HypertensionNCT00803660
Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
An observational study of Hypertension and Type 2 Diabetes, run by AstraZeneca at 19 sites in Vietnam.
Trial summary
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypertension, Type 2 Diabetes
- How many people
- 1,060 participants
- Where
- 19 sitesVietnam
- Study dates
- Nov 2008to May 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: type 2 diabetic patients who are currently using antihypertensive treatment for at least 3 months, with same regimen for a minimum of 4 weeks prior to the survey
Who may be able to join
- Provision of written informed consent
- Patient was diagnosed with type 2 diabetes
- Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey
Who cannot join
- Patients are critically ill, had mental health problems or difficulty in communication
- Patients who are unwilling or unable to provide informed consent
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
Trial locations and contacts
19 sites in 1 country.
19 sites in 1 country
Vietnam19 sites
Research Site
Bạc Liêu, Bac Lieu
Research Site
Bien Hoa, Dong Nai
Research Site
Buon Me Thuoc, Dak Lak
Research Site
Ca Mau, Ca Mau
Research Site
Can Tho, Can Tho City
Research Site
Châu Đốc, An Giang
Research Site
Da Nang, Da Nang
Research Site
Dong Thap, Dong Thap
Research Site
Haiphong
Research Site
Hanoi, Hanoi
Research Site
Ho Chi Minh City
Research Site
Huế, Thua Thien
Research Site
Kiến Giang, Kien Giang
Research Site
Nam Định, Nam Dinh
Research Site
Nha Trang, Khanh Hoa
Research Site
Qui Nhon, Binh Dinh
Research Site
Thái Bình, Thai Binh
Research Site
Thống Nhất, Dong Nai
Research Site
Tiền Giang, Tien Giang
About this study
Official title: In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=<7%. To observe the proportion of patients achieving fasting plasma glucose<110 mg%. To identify factors for not achieving BP<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .
- Conditions
- Hypertension, Type 2 Diabetes
- Keywords
- hypertension, BP, diabetes, anti-hypertensive treatment, ACE-I, ARB
- Medical subject headings
- Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus
What is being measured
The primary outcome is the main question the study is designed to answer.
The number of patients achieving the BP<130/80 mmHg
The percentage of patients achieving the BP<130/80 mmHg
Secondary outcomes (5)
The number and percentage of patients achieving the BP<130/80 mmHg by treatment groups
The number and percentage of patients achieving HbA1c=<7%
The number and percentage of patients achieving the FPG<110 mg%
The association between unachievement of BP<130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...)
The number and percentage of patients with positive proteinuria by treatment groups
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2008 (estimated)
- Study startNov 2008
- Study completionMay 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Cross-sectional
- Enrolment
- 1,060 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Dang Van Phuoc, PhD., Principal investigator, University of Medicine and Pharmacy of HCMCPham Nguyen Vinh, PhD., Principal investigator, Tam Duc Heart HospitalPham Gia Khai, PhD., Principal investigator, Vietnam Heart AssociationNguyen Thy Khue, PhD, Principal investigator, Endocrinology and Diabetes Association of HCMC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00803660
- Sponsor's protocol ID
- NIS-CVN-DUM-2008/1
- Status last verified
- Jul 2009
- First submitted
- 3 Dec 2008
- Last updated
- 9 Jul 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.
- ClinicalTrials.gov ID
- NCT00803660
- Acronym / sponsor ID
- NIS-CVN-DUM-2008/1
- Conditions
- Hypertension, Type 2 Diabetes
- Keywords
- hypertension, BP, diabetes, anti-hypertensive treatment, ACE-I, ARB
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,060 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- Nov 2008
- Study completion
- May 2009 (actual)
- First posted
- 5 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive treatment. Data collection for each patient will take place at one visit. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg. To observe the proportion of diabetic patients on antihypertensive treatment reaching the BP<130/80 mmHg by treatment groups. To observe the proportion of patients achieving a therapeutic glycemic response defined as HbA1c=<7%. To observe the proportion of patients achieving fasting plasma glucose<110 mg%. To identify factors for not achieving BP<130/80 mmHg. To describe percentage of patients with positive proteinuria (including microalbuminuria) by treatment groups .
Study design
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- type 2 diabetic patients who are currently using antihypertensive treatment for at least 3 months, with same regimen for a minimum of 4 weeks prior to the survey
Key inclusion criteria (3 listed)
- Provision of written informed consent
- Patient was diagnosed with type 2 diabetes
- Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey
Key exclusion criteria (3 listed)
- Patients are critically ill, had mental health problems or difficulty in communication
- Patients who are unwilling or unable to provide informed consent
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The number of patients achieving the BP<130/80 mmHg
The percentage of patients achieving the BP<130/80 mmHg
5 secondary outcomes
The number and percentage of patients achieving the BP<130/80 mmHg by treatment groups
The number and percentage of patients achieving HbA1c=<7%
The number and percentage of patients achieving the FPG<110 mg%
The association between unachievement of BP<130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...)
The number and percentage of patients with positive proteinuria by treatment groups
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2009.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dang Van Phuoc, PhD. principal investigator
University of Medicine and Pharmacy of HCMC
Pham Nguyen Vinh, PhD. principal investigator
Tam Duc Heart Hospital
Pham Gia Khai, PhD. principal investigator
Vietnam Heart Association
19 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypertension and Type 2 Diabetes, run by AstraZeneca at 19 sites in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Jul 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 19 sites in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The number of patients achieving the BP<130/80 mmHg. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2009.